Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Epigenetics in Drug Discovery

Emmanuel Demont's Biography

Emmanuel Demont, Director, GlaxoSmithKline

Emmanuel Demont completed his PhD in France (Ecole Polytechnique, Paris), followed by a post-doc in Canada with Professor Hanessian, before moving to industrial positions in the UK, at Roche then at GSK from 2001 onwards. He has worked in multiple areas (HIV, Alzheimers, GI, inflammation) from T2L effort to candidate selection. He is currently co-leading the chemistry group of the Epigenetic DPU at GSK Stevenage and is a member of the DPU leadership team. He is accountable for the progression of all early stage programs and for the identification of clinical candidates against various epigenetic targets. He is the author of more than 70 patents and publications.

Emmanuel Demont Image

Discovery Of Low Nanomolar, Selective And Cell Permeable ATAD2 Bromodomain Inhibitors

Monday, 6 March 2017 at 16:15

Add to Calendar ▼2017-03-06 16:15:002017-03-06 17:15:00Europe/LondonDiscovery Of Low Nanomolar, Selective And Cell Permeable ATAD2 Bromodomain

This talk will describe how we identified a highly selective and potent chemical probe for the ATAD2 bromodomain from a weak unselective hit, with a particular focus on how we gained BET selectivity and cell permeability.

Add to Calendar ▼2017-03-06 00:00:002017-03-07 00:00:00Europe/LondonEpigenetics in Drug